Clinical trials: Oncologic
Lung Cancer
Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology
Lung cancer kills 160,000 patients annually; this represents 28% of all US cancer deaths. The overall year survival rate has only improved from 12% to 17% in 33 years.
- Trial name
- NCT02123797
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Baptist Memorial Health Care Corporation
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Oncology, Solid Tumor, Adult
Stratification of Patients in Oncogeriatrics and Personalization of Interventions
Multicenter randomized controlled trial. Patients will be randomly assigned to the control group or the intervention group in each of the health centers.
- Trial name
- ONKO-FRAIL (NCT05131113)
- Testing
- Physical exercise
- Where
- 3 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Biogipuzkoa Health Research Institute
Vulvar Cancer, Ovarian Cancer
Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery
The purpose of this study is to help test an idea designed to foster more supportive talk between providers (doctors or nurse practitioners), patients, and caregivers during an outpatient oncology appointment.
- Conditions
- Vulvar Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer
- Trial name
- PRECursOr (NCT05995860)
- Testing
- Intervention group triads
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Indiana University
Cancer
Clinical Utilization of Newly Approved Oncology Medications
The efficacy and safety of different medications vary from one individual to another and from one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic and pharmacoepidemiology has evolved recently.
- Trial name
- NCT02783885
- Testing
- immunotherapy
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 100 people
- Sponsor
- National Guard Health Affairs
Febrile Neutropenia, Neutropenia
Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients
Febrile neutropenia (FN) is a major life-threatening treatment complication in cancer patients undergoing intensive chemotherapy. Endogenous flora is considered to be one of the main sources of infections during neutropenia.
- Conditions
- Febrile Neutropenia, Neutropenia, Infection in an Immunocompromised Host, Cancer
- Trial name
- FENSY (NCT02544685)
- Testing
- Probio-Fix Inum, Beneo Synergy 1
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- S&D Pharma SK s.r.o.
Non-Small Cell Lung Cancer (NSCLC)
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with…
- Trial name
- NCT03260491
- Testing
- HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
- Where
- 37 sites in United States, Japan and 4 more
- Volunteers
- 312 people
- Sponsor
- Daiichi Sankyo
Gynecologic Cancer, Chemotherapy Effect
Improve Cancer-related Cognitive Impairment
Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments.
- Conditions
- Gynecologic Cancer, Chemotherapy Effect, Chemo-brain, Cancer-related Cognitive Difficulties
- Trial name
- NCT05864274
- Testing
- Cognitive training application
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Breast Cancer, Colorectal Cancer
Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon
Symptoms related to the disease and/or treatment are common in cancer patients and can affect patient health-related quality of life (HRQol). Unfortunately these symptoms can be underestimated and underreported by the physician.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- QOLIBRY (NCT02844608)
- Testing
- Quality of Life Questionnaires
- Where
- France
- Volunteers
- 152 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cancer, Smoking
Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)
The goal of this study is to determine whether the novel smartphone application designed specifically for cancer patients to quit smoking (Quit2Heal) provides higher quit rates than the current standard smoking cessation app.
- Trial name
- Quit2Heal (NCT03600038)
- Testing
- Experimental smoking cessation smartphone app, Standard of care smoking cessation smartphone app
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-small Cell Lung Cancer
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00050674
- Testing
- Filgrastim-SD/01
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Schwartzberg, Lee, M.D.
Cancer
A Study of a Telemedicine Program for Older Adults With Cancer
The purpose of this study is to find out if a telemedicine program for older adults in cancer treatment is a practical way to understand and meet these participants' unique needs.
- Trial name
- NCT04917848
- Testing
- Tele-Geriatric Oncology program
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma
Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma
This trial is a prospective, monocentric, with minimal risks and constraints study, conducted in patients with Soft Tissue Sarcoma (STS) of the limbs and trunk with indication for neoadjuvant radiotherapy (RT).
- Conditions
- Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma
- Trial name
- SarQuantIRM (NCT05684874)
- Testing
- Neoadjuvant RT, Pre-radiotherapy mpMRI, Post-radiotherapy mpMRI
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Lymphoma, Multiple Myeloma
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Primary objective 1) To assess whether oncologic and hematologic patients develop a protective immunological response after pandemic Influenza A (H1N1) vaccine Secondary objectives 1.
- Conditions
- Lymphoma, Multiple Myeloma, Myeloproliferative Disease
- Trial name
- NCT01394640
- Testing
- Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Paolo Corradini
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of…
- Trial name
- NCT04460911
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Pfizer
Lung Cancer, Lung Cancer Stage I
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing…
- Conditions
- Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II
- Trial name
- NCT03290534
- Testing
- CivaSheet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CivaTech Oncology
Cervical Intraepithelial Neoplasia, Cervical Neoplasms
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of people who have had the treatment.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix
- Trial name
- NCT04266093
- Testing
- GeneTherapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Cancer
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a…
- Trial name
- NCT04319224
- Testing
- Vopratelimab, Ipilimumab, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Jounce Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.